The company is currently evaluating its lead clinical-stage candidate, epetraborole, a bacterial leucyl-tRNA synthetase inhibitor, for nontuberculous mycobacteria (NTM) lung disease and acute ...
Along with its support of alpibectir, the pharma group is also running trials of another novel antitubercular drug, an inhibitor of the bacterial enzyme leucyl t-RNA synthetase (LeuRS), codenamed ...
As noted above, stellate cell activation is the central event in hepatic fibrosis. Activation consists of 2 major phases: (1) initiation (also called apreinflammatory stage) and (2) perpetuation ...